D. Boral Capital Reaffirms Buy Rating for Anixa Biosciences (NASDAQ:ANIX)

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They currently have a $10.00 price target on the stock. D. Boral Capital’s target price points to a potential upside of 338.60% from the stock’s current price.

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Anixa Biosciences in a research report on Tuesday, November 19th.

Anixa Biosciences Stock Performance

Shares of ANIX stock opened at $2.28 on Tuesday. The firm has a fifty day moving average of $2.86 and a 200-day moving average of $3.03. The stock has a market cap of $73.37 million, a price-to-earnings ratio of -5.85 and a beta of 0.82. Anixa Biosciences has a 52-week low of $2.07 and a 52-week high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings data on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02. On average, sell-side analysts predict that Anixa Biosciences will post -0.42 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Amit Kumar purchased 43,000 shares of the stock in a transaction dated Wednesday, January 15th. The stock was bought at an average cost of $2.23 per share, with a total value of $95,890.00. Following the purchase, the chief executive officer now directly owns 559,925 shares in the company, valued at $1,248,632.75. The trade was a 8.32 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 22.60% of the company’s stock.

Institutional Trading of Anixa Biosciences

Large investors have recently made changes to their positions in the company. Concorde Asset Management LLC acquired a new stake in Anixa Biosciences during the 2nd quarter worth approximately $31,000. International Assets Investment Management LLC increased its position in shares of Anixa Biosciences by 170.0% during the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after purchasing an additional 23,800 shares during the last quarter. Tyler Stone Wealth Management grew its position in shares of Anixa Biosciences by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after acquiring an additional 21,008 shares during the period. Virtu Financial LLC bought a new position in Anixa Biosciences during the third quarter worth about $34,000. Finally, Westside Investment Management Inc. increased its holdings in shares of Anixa Biosciences by 151.8% during the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after acquiring an additional 21,100 shares during the last quarter. Institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.